Detection of gene mutations using the protein truncation test

Advances in Anatomic Pathology

Volumn 4, Issue 2, 1997, Pages 123-133

  Sellner, Loryn N ^a   Turbett, Gavin R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0009681503     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-199703000-00036     Document Type: Review

References (84)

1. Roest PAM, Roberts RG, Sugino S, van Ommen GJB, den Dunnen JT. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet 1993;2:1719-21.
2. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
3. Sheffield V, Cox DR, Lerman LS, Myers RM. Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base-changes. Proc Natl Acad Sci USA 1989;86:232-6.
4. Cotton RGH, Rodrigues NR, Campbell DR. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci USA 1988;85:4397-4401.
5. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA: DNA duplexes. Science 1985;230:1242-6.
6. White MB, Carvalho M, Derse D, O'Brien SJ, Dean M. Detecting single base substitutions as heteroduplex polymorphisms. Genomics 1992;12:301-6.
7. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993;16:325-32.
8. Theophilus BDM, Latham T, Grabowski GA, Smith FI. Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human β-glucosidase gene. Nucleic Acids Res 1989;17:7707-22.
9. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-7.
10. Presser J, Condie A, Wright M, et al. APC mutation analysis by chemical cleavage of mismatch and a protein truncation assay in familial adenomatous polyposis. Br J Cancer 1994;70:841-6.
11. van der Luit R, Khan PM, Vasen H, et al. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 1994;20:1-4.
12. Liu B, Parsons RE, Hamilton SR, et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 1994;54:4590-4.
13. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-33.
14. Mandl M, Paffenholz R, Friedl W, Caspari R, Sengteller M, Propping P. Frequency of common and novel inactivating APC mutations in 202 families with familial adenomatous polyposis. Hum Mol Genet 1994;3:181-4.
15. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian susceptibility gene, implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
16. Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
17. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in 10 families. Nat Genet 1994;8:399-404.
18. Breast Cancer Information Core. Open access on-line breast cancer mutation data base. 1996. http://www.nchgr.nih.gov/Intramural-research/Lab- transfer/Bic/index.html.
19. Cariello NF, Cui L, Beroud C, Soussi T. Database and software for the analysis of mutations in the human p53 gene. Cancer Res 1994;54:4454-60.
20. Harris C. The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: insights from the mutaional analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-9.
21. Nijmegen) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem 1988;263:17913-6.
22. Atweh GF, Brickner HE, Zhu X-X, Kazazian HH, Forget BG. New amber mutation in a β-thalassemic gene with nonmeasurable levels of mutant messenger RNA in vivo. J Clin Invest 1988;82:557-61.
23. Kadowaki T, Kadowaki H, Rechter MM, et al. Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest 1990;86:254-64.
24. Kadowaki T, Bevins CL, Cama A, et al. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 1988;240:787-90.
25. Murday V, Slack J. Inherited disorders associated with colorectal cancer. Cancer Surv 1989;8:139-57.
26. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
27. Kinder KW, Nilbert NC, Su LK, et al. Identifîcaion of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
28. Graden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
29. Easton DF, Bishop DT, Ford D, Crockford GP. Breast cancer linkage consortium. Genetic linkage analysis in familial breast and ovarian cancer results from 214 families. Am J Hum Genet 1993;52:678-701.
30. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
31. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the 17q-linked breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
32. Hogervorst FBL, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
33. Plummer SJ, Anton-Culver H, Webster L, et al. Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet 1995;4:1989-91.
34. Lancaster JM, Cochran CJ, Brownlee HA, et al. Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. J Natl Cancer Inst 1996;88:552-4.
35. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Eng J Med 1996;334:143-9.
36. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
37. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
38. Luce MC, Marra G, Chauhan DP, et al. In vitro transcription/translation assay for the screening of hMLH1 and hMSH2 mutations in familial colon cancer. Gastroenterology 1995;109:1368-74.
39. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;268:258-61.
40. Papadopoulos N, Nicolaides NC, Wei Y-F, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-9.
41. Wijnen J, Khan PM, Vasen H, et al. Majority of the hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am J Hum Genet 1996;58:300-7.
42. Tannergard P. Lipford JR, Kolodner R, Frodin JE, Nordenskjold M, Lindblom A. Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families. Cancer Res 1995;55:6092-6.
43. Han HJ, Maruyama M, Baba S, Park JG, Nakamura Y. Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non-polyposis colorectal cancer. Hum Mol Genet 1995;4:237-42.
44. Stumpf DA, Alksne JF, Annegers JF, et al. Neurofibromatosis. Arch Neurol 1988;45:575-8.
45. Li Y, O'Connell P, Breidenbach HH, et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995;25:9-18.
46. Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991;13:672-80.
47. Cawthon RM, Weiss R, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
48. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 gene locus. Cell 1990;62:187-92.
49. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;429:182-6.
50. Upadhyaya M, Maynard J, Osborn M, et al. Characterisation of germline mutations in the neurofibromatosis type 1 (NF1) gene. J Med Genet 1995;32:706-10.
51. Upadhyaya M, Shaw DJ, Harper PS. Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene. Hum Mutat 1994;4:83-101.
52. Heim RA, Kam-Morgan LNW, Binnie CG, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995;44:975-81.
53. Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991;70:99-117.
54. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-94.
55. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
56. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals a similarity to cell cycle regulators in different species. Hum Mol Genet 1995;4:2025-32.
57. Rasio D, Negrini M, Croce CM. Genomic organization of the ATM locus involved in ataxia-telangiectasia. Cancer Res 1995;55:6053-7.
58. HGMD - Human gene mutation database 1996. http://www.cf.ac.uk/uwcm/mg/ hgmd0.html.
59. Telatar M, Wang Z, Udar N, et al. Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am J Hum Genet 1996;59:40-4.
60. den Dunnen JT, Grootscholten PM, Bakker E, van Broeckhoven C, Pearson PL, van Ommen GJB. Topography of the DMD gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989;45:835-47.
61. Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics 1992;16:536-8.
62. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988;16:11141-6.
63. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990;86:45-8.
64. Roberts RG, Gardner RJ, Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat 1994;4:1-11.
65. Gardner RJ, Bobrow M, Roberts RG. The identification of point mutations in Duchenne muscular dystrophy patients by using reverse-transcription PCR and the protein truncation test. Am J Hum Genet 1995;57:311-20.
66. Roest PAM, Roberts RG, van der Tuijn AC, Heikoop JC, van Ommen G-JB, den Dunnen JT. Protein truncation test (PTT) to rapidly screen the DMD gene for translation terminating mutations. Neuromuscul Disord 1993;3:391-4.
67. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
68. Wellenreuther R, Kraus JA, Lonartz C, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146:827-32.
69. Merel P, Haong-Xuan K, Sanson M, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995;13:211-6.
70. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-4.
71. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-50.
72. Ng H-K, Lau K-M, Tse JYM, et al. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 1995;37:764-73.
73. Bishop DT, Cannon-Albright L, McLellan T, et al. Segregation and linkage anslysis of 9 Utah breast cancer pedigrees. Genet Epidemiol 1988;5:151-69.
74. Tavtigian SV, Simard J, Rommens J, et al. The complete RBCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
75. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993;260:1317-20.
76. Gnarra JR, Tory K, Weng Y, et al. Muterions of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
77. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von-Hippel-Lindau-disease tumour-suppressor gene in non-familial clear-cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
78. Bailly M, Bain C, Favrot M-C, Ozturk M. Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer 1995;63:660-4.
79. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
80. Chen F, Kishida T, Yao M, et al. Germ line mutations in the von Hippel-Lindau tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
81. Vogel F. Genetics of retinoblastoma. Hum Genet 1979;52:1-54.
82. Lee W-H. Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-HP. Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 1987;235:1394-9.
83. Lee W-H, Shew J-Y, Hong FD, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-5.
84. McGee TL, Yandell DW, Dryja TP. Structure and partial genomic sequence of the human retinoblastoma susceptibility gene. Gene 1989;80:119-28.